PLUS THERAPEUTICS, Inc. - Common Stock (PSTV)
0.5450
+0.1950 (55.71%)
Plus Therapeutics Inc is a biotechnology company focused on developing innovative therapies for cancer treatment
The company utilizes a proprietary nanoscale particle technology aimed at delivering targeted, localized therapies to improve patient outcomes while minimizing systemic side effects. Their pipeline includes treatments designed to address various types of cancer, with a particular emphasis on rare and hard-to-treat indications. Through its research and development efforts, Plus Therapeutics is committed to advancing the science of cancer care and providing new options for patients facing challenging diagnoses.

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · March 6, 2025

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · March 5, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.
Via Chartmill · March 5, 2025

PLUS THERAPEUTICS, Inc. (NASDAQPSTV) shares are trading higher on Wednesday.
Via Benzinga · November 1, 2023

Via Benzinga · November 7, 2024

Via Benzinga · September 30, 2024

Via Benzinga · September 30, 2024

Via Benzinga · September 27, 2024

PSTV stock results show that Plus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024

PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 15, 2024

Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion.
Via Benzinga · April 22, 2024

PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 5, 2024

Via Benzinga · November 20, 2023

Companies Reporting Before The Bell • NIO (NYSENIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
Via Benzinga · March 5, 2024

The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · November 9, 2023

Gainers
Via Benzinga · November 1, 2023

Gainers
Via Benzinga · November 1, 2023

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!
Via InvestorPlace · November 1, 2023

Via Benzinga · October 31, 2023

Companies Reporting Before The Bell • BBVA (NYSEBBVA) is likely to report earnings for its third quarter. • BP NYSE:BPNYSEBP)
Via Benzinga · October 31, 2023